<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Avian influenza virus vaccine (H5N1) (United States: Availability limited to CDC distribution from Strategic National Stockpile in consultation with local health department): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Avian influenza virus vaccine (H5N1) (United States: Availability limited to CDC distribution from Strategic National Stockpile in consultation with local health department): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Avian influenza virus vaccine (H5N1) (United States: Availability limited to CDC distribution from Strategic National Stockpile in consultation with local health department): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8922" href="/d/html/8922.html" rel="external">see "Avian influenza virus vaccine (H5N1) (United States: Availability limited to CDC distribution from Strategic National Stockpile in consultation with local health department): Drug information"</a> and <a class="drug drug_patient" data-topicid="127111" href="/d/html/127111.html" rel="external">see "Avian influenza virus vaccine (H5N1) (United States: Availability limited to CDC distribution from Strategic National Stockpile in consultation with local health department): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56347766"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Audenz</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56347767"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Arepanrix;</li>
<li>Foclivia</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F54148476"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Vaccine</span>;</li>
<li>
<span class="list-set-name">Vaccine, Inactivated (Viral)</span></li></ul></div>
<div class="block dop drugH1Div" id="F50539486"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b2db45f-0a0e-45ab-b69a-e4766dadba79">Influenza A subtype H5N1, immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza A subtype H5N1, immunization</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Available vaccines are manufactured differently; dose volumes are different (eg, 0.25 mL vs 0.5 mL per dose); use caution when verifying product selection and dose volume.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GlaxoSmithKline product</i>
<i>(AS03-adjuvanted):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months, Children, and Adolescents ≤17 years: IM: 0.25 mL, followed by a second 0.25 mL dose 21 days later.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: IM: 0.5 mL, followed by a second 0.5 mL dose 21 days later.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Seqirus product (MF59-adjuvanted: Audenz, Foclivia [Canadian product]):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months, Children, and Adolescents: IM: 0.5 mL, followed by a second 0.5 mL dose 21 days later.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51159580"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51159581"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F4598894"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8922" href="/d/html/8922.html" rel="external">see "Avian influenza virus vaccine (H5N1) (United States: Availability limited to CDC distribution from Strategic National Stockpile in consultation with local health department): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8a2b7e0f-39de-4c22-ba77-e963820927e8">Influenza A prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza A (H5N1) prevention: Note:</b> There are no data to support the interchangeability of vaccines.</p>
<p style="text-indent:-2em;margin-left:4em;">Seqirus (MF59-adjuvanted: Audenz, Foclivia [Canadian product]) and GlaxoSmithKline (AS03-adjuvanted) products: <b>IM:</b> 0.5 mL followed by a second 0.5 mL dose administered 21 days later.</p>
<p style="text-indent:-2em;margin-left:4em;">Sanofi Pasteur product: Adults 18 to 64 years of age: <b>IM:</b> 1 mL followed by second 1 mL dose administered ~28 days later (acceptable range: 21 to 35 days).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990237"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987572"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F4598881"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Actual percentages may vary by product and age group.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (6% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children and adolescents: ≤17%), anorexia (children and adolescents: 14% to 29%), change in appetite (infants and children: 18%), diarrhea (≤17%), nausea (≤17%), vomiting (children and adolescents: ≤17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (≤34%), induration at injection site (≤15%), pain at injection site (36% to 83%), swelling at injection site (adults: ≤15%; infants, children, and adolescents: 28% to 29%), tenderness at injection site (adults: 70%; infants and children: 56%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (infants and children: 25% to 38%), fatigue (20% to 34%), headache (3% to 35%), irritability (infants and children: ≤51%), malaise (16% to 25%), shivering (adults: 17%; children and adolescents: 4% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (10% to 25%), myalgia (9% to 45%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (3% to 22%), fussiness in an infant or toddler (≤51%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastroenteritis (children and adolescents: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Itching at injection site (adults: 2%), warm sensation at injection site (adults: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (older adults: 4%), dizziness (adults: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bruising at injection site (adults)</p></div>
<div class="block coi drugH1Div" id="F4598877"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Seqirus products (Audenz, Foclivia [Canadian product]) (MF59-adjuvanted): Severe allergic reactions (eg, anaphylaxis) to any component of the vaccine or after a previous dose of an influenza vaccine. <b>Note:</b> The Foclivia product labeling states that administration to persons with a history of anaphylaxis to a vaccine component may be appropriate during a pandemic situation if acute medical facilities/treatment are available.</p>
<p style="text-indent:-2em;margin-left:2em;">GlaxoSmithKline product (AS03-adjuvanted): Severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of an influenza vaccine.</p>
<p style="text-indent:-2em;margin-left:2em;">Sanofi Pasteur product: There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F4598878"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis or tendinopathy) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); more often reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Postpone administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Guillain-Barré syndrome: Use with caution in patients with a history of Guillain-Barré syndrome (GBS); patients with history of GBS have a greater likelihood of developing GBS than those without. Although data specific to the influenza A virus vaccine (H5N1) are unavailable, the following guidance is based on seasonal influenza vaccines: As a precaution, the Advisory Committee on Immunization Practices (ACIP) recommends that patients with a history of GBS and who are at low risk for severe influenza complications and patients known to have experienced GBS within 6 weeks following previous vaccination should generally not be vaccinated (consider influenza antiviral chemoprophylaxis in these patients). The benefits of vaccination may outweigh the potential risks in persons with a history of GBS who are also at high risk for complications of influenza (CDC/ACIP [Grohskopf 2019]). Studies of patients who received the trivalent inactivated influenza vaccine or the monovalent H1N1 influenza vaccine have shown the risk of GBS is lower with vaccination than with influenza infection (Baxter 2013; Greene 2013; Kwong 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or nonlive) for which a person is eligible at a single visit, unless contraindications exist. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand name is unavailable (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Postpone vaccination during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]) if appropriate; may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines. Nonlive vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible; nonlive vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2023]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Sanofi Pasteur product has not been evaluated in patients ≥65 years of age</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Chicken egg protein: Some products may be manufactured with chicken egg protein.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kanamycin: Some products may be manufactured with kanamycin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neomycin: Some products may be manufactured with neomycin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thimerosal: Some products may contain thimerosal; hypersensitivity reactions may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2023]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2023]).</p></div>
<div class="block prod-avail drugH1Div" id="F22803117"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Products will not be commercially available; distribution will be limited as part of the US Strategic National Stockpile.</p></div>
<div class="block foc drugH1Div" id="F4598899"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, emulsion [monovalent]:</p>
<p style="text-indent:-2em;margin-left:4em;">GlaxoSmithKline product: Adjuvanted Hemagglutinin [A/Indonesia/05/2005 (H5N1)] 3.75 mcg/0.5 mL (5 mL) [contains egg protein, polysorbate 80, and thimerosal]</p>
<p style="text-indent:-2em;margin-left:4em;">Seqirus product: Adjuvanted Hemagglutinin [A/turkey/Turkey/1/2005 NIBRG-23 (H5N1)] 7.5 mcg/0.5 mL (0.5 mL, 5 mL) [contains polysorbate 80; 0.5 mL prefilled syringe contains mercury; 5 mL vial contains thimerosal]</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, suspension [monovalent]:</p>
<p style="text-indent:-2em;margin-left:4em;">Sanofi Pasteur product: Hemagglutinin [A/Vietnam/1203/2004 (H5N1)] 90 mcg/mL (5 mL) [contains chicken and egg protein, porcine gelatin, and thimerosal]</p></div>
<div class="block geq drugH1Div" id="F4598867"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F56347755"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, emulsion [monovalent]:</p>
<p style="text-indent:-2em;margin-left:4em;">GlaxoSmithKline product: Adjuvanted Hemagglutinin [A/Indonesia/5/2005 (H5N1)] 3.75 mcg/0.5 mL (5 mL) [contains egg protein, polysorbate 80, and thimerosal]</p>
<p style="text-indent:-2em;margin-left:4em;">Seqirus product: Adjuvanted Hemagglutinin [A/Vietnam/1194/2004 (H5N1)] 7.5 mcg/0.5 mL (0.5 mL, 5 mL) [contains polysorbate 80; 5 mL vial contains thimerosal]</p></div>
<div class="block adip drugH1Div" id="F55509328"><span class="drugH1">Additional Information</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>H5N1 influenza virus strain:</i></p>
<p style="text-indent:-2em;margin-left:4em;">GlaxoSmithKline product: A/Indonesia/05/2005</p>
<p style="text-indent:-2em;margin-left:4em;">Seqirus products:</p>
<p style="text-indent:-2em;margin-left:6em;">Audenz: A/turkey/Turkey/1/2005 NIBRG-23</p>
<p style="text-indent:-2em;margin-left:6em;">Foclivia [Canadian product]: A/Vietnam/1194/2004</p>
<p style="text-indent:-2em;margin-left:4em;">Sanofi Pasteur product: A/Vietnam/1203/2004</p></div>
<div class="block accres drugH1Div" id="F11233933"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Commercial distribution is not planned. The vaccine will be included as part of the US Strategic National Stockpile. It will be distributed by public health officials if needed.</p></div>
<div class="block admp drugH1Div" id="F52622711"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IM: For IM administration only. Inspect for particulate matter and discoloration prior to administration. Administer into the deltoid muscle in children and adolescents; the anterolateral thigh is preferred for infants ≥6 months. Do not inject into areas where there may be a major nerve trunk, including the gluteal region. If injected in the deltoid muscle, use proper injection technique (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, adolescents should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). US law requires that the date of administration; the vaccine manufacturer; lot number of vaccine; and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>
<p style="text-indent:-2em;margin-left:4em;">GlaxoSmithKline product (AS03-adjuvanted): If vaccine is stored under refrigeration after mixing, bring to room temperature prior to administration (minimum 15 minutes). Mix thoroughly by inversion prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Seqirus product (MF59-adjuvanted: Audenz, Foclivia [Canadian product]): Gently shake syringe prior to administration; appearance should be milky-white.</p>
<p style="text-indent:-2em;margin-left:4em;">For patients at risk of hemorrhage following IM injection, the vaccine should be administered IM if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F4598895"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IM: </b>For IM administration only. Gently shake prior to use. Inspect for particulate matter and discoloration prior to administration. Administer into the deltoid muscle; do not inject into the gluteal region or areas where there may be a major nerve trunk. Use proper injection technique in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, patients should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>
<p style="text-indent:-2em;margin-left:2em;">GlaxoSmithKline product (AS03-adjuvanted): If vaccine is stored under refrigeration after mixing, bring to room temperature prior to administration (minimum 15 minutes). Mix thoroughly by inversion prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Seqirus product (MF59-adjuvanted: Audenz, Foclivia [Canadian product]): Gently shake prior to administration; appearance should be milky white.</p>
<p style="text-indent:-2em;margin-left:2em;">For patients at risk of hemorrhage following IM injection, the vaccine should be administered IM if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F4598887"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Audenz, Foclivia [Canadian product], and Sanofi Pasteur products: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard if frozen. Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">GlaxoSmithKline product (adjuvanted): Prior to mixing, the H5N1 antigen and AS03 adjuvant vials should be stored in a refrigerator between 2°C and 8°C (36°F and 46°F). Do not freeze. Discard if frozen. Protect from light. After mixing, the vaccine may be stored under refrigeration between 2°C and 8°C (36°F and 46°F) or at room temperature up to 30°C (86°F) for up to 24 hours. Do not freeze. Discard if frozen. Protect from light.</p></div>
<div class="block usep drugH1Div" id="F54148480"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Active immunization against disease caused by the influenza A virus H5N1 subtype contained in the vaccine in patients at increased risk of exposure to the virus (FDA approved in ages ≥6 months and adults). <b>Note:</b> General recommendations for who should be vaccinated are not available (CDC 2019); products are part of US National Stockpile (ie, not commercially available); immunization should be under the direction of public health officials.</p></div>
<div class="block mst drugH1Div" id="F4598861"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Influenza A virus vaccine (H5N1) may be confused with the nonavian or avian strains of influenza virus vaccine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299518"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F4598884"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines 2 weeks prior to starting anti-CD20 B-cell depleting therapies. Vaccination of patients treated with these agents in the past 6 months is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiation of systemic corticosteroids at immunosuppressive doses. Influenza vaccines administered less than 14 days prior to or during such therapy should be repeated 3 months after therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating methotrexate if possible. If vaccination occurs less than 2 weeks prior to or during methotrexate therapy, revaccinate 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Avoid administration of vaccines (inactivated) during treatment with siponimod and for 1 month after discontinuation due to potential decreased vaccine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Influenza virus vaccines are not recommended in the 2 weeks prior to teplizumab treatment, during treatment, or for 6 weeks after treatment. Reduced efficacy of the vaccine may occur if administer to patients taking teplizumab.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccination with inactivated or non-replicating vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during treatment, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F4598874"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies using the H5N1 vaccine GlaxoSmithKline adjuvanted product; animal reproduction studies have not been conducted with the Sanofi Pasteur product. Nonlive viral vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2023]).</p></div>
<div class="block mopp drugH1Div" id="F54148483"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for hypersensitivity and syncope for 15 minutes following administration (ACIP [Kroger 2023]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>
<div class="block pha drugH1Div" id="F4598888"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Promotes active immunity to influenza A H5N1 (avian).</p></div>
<div class="block phk drugH1Div" id="F4598890"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Onset of action: Most persons have antibody protection within 3 weeks (Audenz, GlaxoSmithKline vaccine, and Foclivia [Canadian product]) or 4 weeks (Sanofi Pasteur vaccine) after complete vaccination.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58204864"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aflunov</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Gc Flu H5N1 Multi</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Aflunov</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aflunov</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-18199865">
<a name="18199865"></a>Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al; Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. <i>N Engl J Med</i>. 2008;358(3):261-273.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/18199865/pubmed" id="18199865" target="_blank">18199865</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Audenz (influenza A virus vaccine [H5N1]) [prescribing information]. Holly Springs, NC: Seqirus Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23580737">
<a name="23580737"></a>Baxter R, Bakshi N, Fireman B, et al. Lack of association of Guillain-Barre syndrome with vaccinations. <i>Clin Infect Dis</i>. 2013;57(2):197-204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/23580737/pubmed" id="23580737" target="_blank">23580737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Information on avian influenza. <a href="https://www.cdc.gov/flu/avianflu/index.htm" target="_blank">https://www.cdc.gov/flu/avianflu/index.htm</a>. Updated March 21, 2019. Accessed February 21, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Foclivia.1">
<a name="Foclivia.1"></a>Foclivia (pandemic influenza vaccine) [product monograph]. Kirkland, Quebec, Canada: Seqirus Canada Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc</i> (2003). 2013;53(1):102-103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23840621">
<a name="23840621"></a>Greene SK, Rett MD, Vellozzi C, et al. Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011. <i>PLoS One</i>. 2013;8(6):e67185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/23840621/pubmed" id="23840621" target="_blank">23840621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31441906">
<a name="31441906"></a>Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 influenza season. <i>MMWR Recomm Rep</i>. 2019;68(3):1-21. doi: 10.15585/mmwr.rr6803a1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/31441906/pubmed" id="31441906" target="_blank">31441906</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Influenza A (H5N1) virus monovalent vaccine, adjuvanted [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2016.</div>
</li>
<li>
<div class="reference">
                  Influenza virus vaccine, H5N1 [prescribing information]. Swiftwater, PA: Sanofi Pasteur; April 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</a>. Accessed June 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23810252">
<a name="23810252"></a>Kwong JC, Vasa PP, Campetelli MA, et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. <i>Lancet Infect Dis</i>. 2013;13(9):769-776.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/23810252/pubmed" id="23810252" target="_blank">23810252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21606531">
<a name="21606531"></a>Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. <i>J Infect Dis</i>. 2011;203(12):1729-1738.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/21606531/pubmed" id="21606531" target="_blank">21606531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-OSHA.1">
<a name="OSHA.1"></a>
<i>OSHA Guidance Update on Protecting Employees From Avian Flu (Avian Influenza) Viruses,</i> Washington, DC: US Department of Labor, Occupational Safety and Health Administration; 2006. Available at <a href="http://www.osha.gov/OshDoc/data_AvianFlu/avian_flu_guidance_english.pdf" target="_blank">http://www.osha.gov/OshDoc/data_AvianFlu/avian_flu_guidance_english.pdf </a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837254">
<a name="19837254"></a>Prymula R, Siegrist CA, Chlibek R, et al, “Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,” <i>Lancet</i>, 2009, 374(9698):1339-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/19837254/pubmed" id="19837254" target="_blank">19837254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16571878">
<a name="16571878"></a>Treanor JJ, Campbell JD, Zangwill KM, et al, “Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine,” <i>N Engl J Med</i>, 2006, 354(13):1343-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/16571878/pubmed" id="16571878" target="_blank">16571878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18237269">
<a name="18237269"></a>Zangwill KM, Treanor JJ, Campbell JD, et al, "Evaluation of the Safety and Immunogenicity of a Booster (Third) Dose of Inactivated Subvirion H5N1 Influenza Vaccine in Humans," <i>J Infect Dis</i>, 2008, 197(4):580-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avian-influenza-virus-vaccine-h5n1-united-states-availability-limited-to-cdc-distribution-from-strategic-national-stockpile-in-consultation-with-local-health-department-pediatric-drug-information/abstract-text/18237269/pubmed" id="18237269" target="_blank">18237269</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 127186 Version 45.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
